Previous close | 4.9000 |
Open | 4.9000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 2.00 |
Expiry date | 2024-12-20 |
Day's range | 4.9000 - 4.9000 |
Contract range | N/A |
Volume | |
Open interest | 7 |
Additional results from largest body of evidence on attenuated androgen use in HAE reinforce need for access to safer and more tolerable HAE prophylaxis optionsRESEARCH TRIANGLE PARK, N.C., June 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence showing that patients with hereditary angioedema (HAE) who have normal C1-inhibitor (HAE-nC1-INH) level and function had a reduction in monthly attack rates after starting oral, once-daily O
BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) is possibly approaching a major achievement in its business, so we would...
Helen Thackray, Chief Research & Development Officer of BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 30,000 shares of the company on May 14, 2024.